Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | DGKA | P23743 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8455974 | 0.88 | ALDH1A1 (0.64) | ALDH1A1TDP1TSHRSMN1; SMN2DGKA | |
| SCHEMBL8013757 | 0.81 | ALDH1A1 (0.56) | ALDH1A1TDP1TSHRSMN1; SMN2MGLL | |
| Ether SCHEMBL3121436 | 0.81 | MGLL (0.51) | ALDH1A1MGLL | |
| SCHEMBL52761 | 0.81 | ALDH1A1 (0.54) | ALDH1A1TDP1TSHRUSP2ALOX15 | |
| SCHEMBL13412441 | 0.81 | ALDH1A1 (0.54) | ALDH1A1TDP1TSHRUSP2ALOX15 | |
| SCHEMBL89183 | 0.81 | ALDH1A1 (0.54) | ALDH1A1TDP1TSHRUSP2ALOX15 | |
| SCHEMBL4807800 | 0.81 | TSHR (0.53) | ALDH1A1TDP1TSHRSMN1; SMN2MGLL | |
| SCHEMBL8193710 | 0.80 | DGKA (0.57) | ALDH1A1TDP1TSHRUSP2ALOX15 | |
| SCHEMBL10071470 | 0.80 | MGLL (0.52) | ALDH1A1MGLL | |
| SCHEMBL10071469 | 0.80 | MGLL (0.52) | ALDH1A1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | ALDH1A1 2539/4885TDP1 1380/4885TSHR 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.